Company Overview

PRIME exits® and American HealthCare Capital are pleased to exclusively present a digital dental laboratory opportunity. The Company was established in the mid-2000s as a digital scanning laboratory primarily focused on modern dentistry technology related to the rising popularity of dental implants as a tooth replacement option. What started as a tech-driven project has evolved into a thriving enterprise, offering a comprehensive suite of digital products, advanced treatment planning solutions, and a wealth of educational resources curated by dentists for dentists.

In 2020, a group of visionary investors recognized the potential in the company’s vision and joined their venture. Together, they’ve been on an incredible journey of growth and innovation, driven by a shared passion for transforming the dental industry. The company’s commitment to progress led them to explore the world of AI software for treatment planning, expanding their offerings to include full arch surgical guides, particularly for cases involving toothless patients. Beyond products, they have launched a training academy, approved by the American Academy of General Dentistry-Pace, serving as both an educational hub and a valuable resource for dentists seeking to stay ahead in the ever-evolving technological landscape.

The Company’s commitment to progress led them to explore the world of AI software for treatment planning, expanding their offerings to include full arch surgical guides, particularly for cases involving toothless patients. Beyond products, they have launched a training academy, approved by the American Academy of General Dentistry-Pace, serving as both an educational hub and a valuable resource for dentists seeking to stay ahead in the ever-evolving technological landscape.

Financial Overview

The Company’s business model is based on custom orders prescribed by licensed dentists and a subscription model with recurring revenues. Since 2019, and despite COVID pandemic, the Company revenues have been steady, ranging between $3 million and $4 million with an EBITDA margin of approximately 20%. Between 2019-2024. The revenue declined in 2024 due to loss of some accounts but EBITDA remained about the same. The company expects to generate same revenue and EBITDA or better in 2025. There was a lot of capital expenditures for future growth in 2022, resulting in a lower-than-usual EBITDA.

Asking Price

The present owners/investors, who have played a major role of this business are extending an invitation for collaboration. Whether it’s through a joint-venture model or a majority stake acquisition, they’re seeking the right partner to amplify the current success and explore new horizons together.

The asking price is $3 million.